Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Women's Studies, Bladder Cancer |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/24/2017 |
| Start Date: | January 2017 |
| End Date: | July 2020 |
| Contact: | UC Cancer Institute Clinical Trials Office |
| Email: | kastla@ucmail.uc.edu |
| Phone: | 513-584-7698 |
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in
combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
can be given without causing severe side effects. This study will also test the safety of
this combination and see what effects (good or bad) it has on participants and their cancer.
combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
can be given without causing severe side effects. This study will also test the safety of
this combination and see what effects (good or bad) it has on participants and their cancer.
Inclusion Criteria:
- Pathologically or cytologically proven advanced, metastatic non-squamous non-small
cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian
cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical
cancer.
- Measurable disease
- Life expectancy of greater than 3 months.
- Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.
Exclusion Criteria:
- Untreated or symptomatic brain metastases.
We found this trial at
1
site
Click here to add this to my saved trials
